HOSPITAL UNIVERSITARIO RUBER
Departamento
Essen University Hospital
Essen, AlemaniaPublicaciones en colaboración con investigadores/as de Essen University Hospital (2)
2018
-
Phase Ib study evaluating safety and clinical activity of the anti-HER3 antibody lumretuzumab combined with the anti-HER2 antibody pertuzumab and paclitaxel in HER3-positive, HER2-low metastatic breast cancer
Investigational New Drugs, Vol. 36, Núm. 5, pp. 848-859
2016
-
Final results of the TANIA randomised phase III trial of bevacizumab after progression on first-line bevacizumab therapy for HER2-negative locally recurrent/metastatic breast cancer
Annals of Oncology, Vol. 27, Núm. 11, pp. 2046-2052